Q-omics provides the consensus-scored MAJIN profile across patient tissues and cancer cell-line models. MAJIN expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAJIN is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, MAJIN RNA expression shows 11,548 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where MAJIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAJIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAJIN survival associations across molecular data types. MAJIN RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAJIN RNA expression–survival associations across cancer types. High MAJIN expression shows unfavorable associations in ACC, UCEC and PAAD, but favorable associations in KIRC, CESC and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAJIN RNA expression.
This table summarizes MAJIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAJIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAJIN shows lower tumor expression in THCA, KICH, LUSC, COAD and LIHC and higher tumor expression in LUAD. The THCA box plot shows higher MAJIN RNA expression in normal versus tumor tissue (log2 FC = −0.446, t-test p < 0.001).
This table shows molecular features associated with MAJIN in patient tissues and cancer cell lines. In patient samples, MAJIN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAJIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
